Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity: Research report

Journal of the Peripheral Nervous System

Volumn 13, Issue 4, 2008, Pages 267-274

  Lanzani, Francesca ^a   Mattavelli, Laura ^a   Frigeni, Barbara ^a   Rossini, Fausto ^b   Cammarota, Sara ^b   Petrò, Daniela ^c   Jann, Stefano ^c   Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Divisione di Ematologia   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Bortezomib; Neuropathic pain; Peripheral neuropathy; Toxicology

Indexed keywords

BORTEZOMIB; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUROTOXICITY; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; VISUAL ANALOG SCALE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; ELECTROPHYSIOLOGY; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEUROTOXICITY SYNDROMES; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES;

EID: 58449094350     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00192.x     Document Type: Article

References (39)

1. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR (2005). Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23 : 5943 5949.
2. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007). Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110 : 1042 1049.
3. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R (2006). Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24 : 937 944.
4. Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P (2006). Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 91 : 837 839.
5. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM (2007). Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 8 : 296 306.
6. Cavaletti G, Nobile-Orazio E (2007). Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 92 : 1308 1310.
7. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G (1992). Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 69 : 203 207.
8. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 61 : 1297 1300.
9. Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G (2006). Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11 : 135 141.
10. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C (2007). The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12 : 210 215.
11. Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW (2003). Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60 : 337 340.
12. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E (2007). Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 : 1570 1575.
13. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999). Total neuropathy score: validation and reliability study. Neurology 53 : 1660 1664.
14. Davies AM, Lara PN Jr., Mack PC, Gandara DR (2007). Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13 : S4647 S4651.
15. Dreicer R, Petrylak D, Agus D, Webb I, Roth B (2007). Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13 : 1208 1215.
16. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ (2007). A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 25 : 733 737.
17. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ (2006). Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107 : 916 924.
18. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A (2006). Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24 : 4867 4874.
19. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM (2005). Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 : 667 675.
20. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H (2006). Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91 : 1498 1505.
21. Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ (2007). Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer 7 : 221.
22. Hughes R (2008). NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy? Nat Clin Pract Neurol 4 : 68 69.
23. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC (2004). A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 : 165 172.
24. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J (2005). Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 : 776 783.
25. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R (2007). Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13 : 5291 5294.
26. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J (2005). Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 29 : 587 590.
27. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, Diaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, Garcia-Larana J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF (2007). Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 108 : 2165 2172.
28. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006). Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24 : 4507 4514.
29. Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C, Greco MM, Carella AM Jr., Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A (2006). Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res 30 : 283 285.
30. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD (2005). Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 : 676 684.
31. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC (2005). Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105 : 3058 3065.
32. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M (2007). Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 109 : 2767 2772.
33. Postma TJ, Heimans JJ (2000). Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11 : 509 513.
34. Richardson P, Jagannath S, Colson K (2006). Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol Suppl 13 4 : 1 discussion 8.
35. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 : 2609 2617.
36. San-Miguel J, Blade J (2006). Perspective on the current use of bortezomib in multiple myeloma. Haematologica 91 : 871 872.
37. Stubblefield MD, Slovin S, MacGregor-Cortelli B, Muzzy J, Scher H, Wright J, Esseltine D, Schenkein D, O'Connor OA (2006). An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol 18 : 410 418.
38. Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, Giaccone G (2007). A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 13 : 3642 3651.
39. Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H, Knecht R (2008). Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 134 : 323 330.